Nat. Rev. Clin. Oncol. doi: /nrclinonc

Slides:

Advertisements

Similar presentations

Intensity Modulated Radiation Therapy (IMRT) for Breast Cancer

Advertisements

Toward Magnetic Resonance–Only Simulation: Segmentation of Bone in MR for Radiation Therapy Verification of the Head Huan Yu, PhD, Curtis Caldwell, PhD,

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Response after initial increase in total tumour burden

Figure 3 Response after appearance of a new lesion

Figure 1 Concept of the therapeutic index

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Figure 3 Risk-adapted and response-adapted

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 New functional imaging techniques in lymphoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Figure 5 Identification of mucinous carcinoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Radiotherapeutic Management of Non–Small Cell Lung Cancer in the Minimal Resource Setting Danielle Rodin, MD, Surbhi Grover, MD, MPH, Melody J. Xu, MD,

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 CAR-T-cell design

Figure 2 Examples of histopathological validation

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 2 The association between CD8+ T‑cell density of the tumour

Figure 1 Clinical case study

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

chemotherapy for patients with MC versus those with AC

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 NIR fluorescence is more suitable for

Figure 1 Critical signalling pathways involved in PDAC pathogenesis

Figure 2 Nonmalignant tissue can be spared from radiation

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Median monthly launch price of a new anticancer drug,

Figure 1 Translocations involved in multiple myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Host immune responses, not the radiosensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Radiation neuropathy. Radiation neuropathy. A 69-year-old woman with a history of breast carcinoma and external beam radiation therapy 2 years before imaging.

Figure 2 Carotid artery inflammation detected using 68Ga-DOTATATE-PET

Figure 5 Palliative-care-referral patterns

Figure 2 Variations between planned and delivered doses of radiation

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Cardiol. doi: /nrcardio

Figure 7 Overview of the methodological processes for

Figure 4 Radiogenomics analysis can reveal relationships

Figure 2 Radiomics in cardiology

Figure 1 Overview of the imaging biomarker roadmap

WARNING WARNING WARNING WARNING WARNING WARNING WARNING WARNING

Figure 3 Determination of the primary site

Exposed film demonstrating distinct radiation fields on the skin when the C-arm was rotated between 12° LAO and 12° RAO (16 cm field of view (FOV) on Artis.

A and B, Axial and coronal high-resolution CT images of the larynx in a 73-year-old patient with papillary thyroid cancer and left vocal cord paralysis.

A 50-year-old man with adenocarcinoma of the left lacrimal sac and nasolacrimal duct. A 50-year-old man with adenocarcinoma of the left lacrimal sac and.

Figure 1 Gene-expression quantification methods

A, pretreatment CT scan of pelvic lymphadenopathy (identified by white arrow) in 1 patient with documented response to 1α-OH-D2. A, pretreatment CT scan.

Patient 10. Patient 10. A 67-year-old man after radiation therapy at an outside hospital for base-of-tongue cancer. A and B, Axial contrast-enhanced CT.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure MRI T1 coronal images show homogenous hyperintense lesion involving the right trigeminal nerve root (white arrows) in A and B and Meckel's cave.

Presentation transcript:

Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2015.171 Figure 6 Strategies to reduce incidental cardiac exposure to radiation in patients with left-sided breast cancer Figure 6 | Strategies to reduce incidental cardiac exposure to radiation in patients with left-sided breast cancer. a | Coronal CT image at free breathing. The thick white line highlighted by the arrow is the heart contour during a deep inspiratory breath-hold, with the heart being displaced inferiorly, medially and somewhat posteriorly, away from the left breast. b | Axial CT image showing positioning of the tangential radiation therapy beam with the patient in the prone position. The breast tissue falls anteriorly, thus allowing the posterior border of the tangential beam to exclude a portion of the heart. c | DRR of the Beam's eye view of a tangent field with a conformal hart block, and d | photograph of the skin of a patient showing conformal shaping of the radiation field and inclusion of a 'heart block'. These strategies are often used concurrently to avoid exposing the heart to radiation. DRR, digitally reconstructed radiograph. Zagar, T. M. et al. (2015) Breast cancer therapy-associated cardiovascular disease Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2015.171